Abstract
Epinephrine (E) and sympathetic nerve stimulation were described by Thomas Renton Elliott in 1905 for the first time. Dopamine (DA), norepinephrine (NE), E, and serotonin (5-HT) belong to the classic biogenic amines (or monoamines). Parkinson’s disease (PD) is among the diseases in which it has been established that catecholamines may account for the neurodegeneration of central and peripheral catecholamine neural systems. PD is a chronic and progressive neurological disorder characterized by resting tremor, rigidity, and bradykinesia, affecting 2% of individuals above the age of 65 years. This disorder is a result of degeneration of DA-producing neurons of the substantia nigra and a significant loss of noradrenergic neurons in the locus coeruleus. In PD and other related neurodegerative diseases, catecholamines play the role of endogenous neurotoxins. Catechol-O-methyltransferase (COMT) and/or monoamine oxidase (MAO) catalyze the metabolism of monoamines. However, the monoamine transporters for DA, NE, and 5-HT namely DAT, NET, and SERT, respectively regulate the monoamine concentration. The metabolism of catecholamines and 5-HT involves common factors. Monoamine transporters represent targets for many pharmacological agents that affect brain function, including psychostimulators and antidepressants. In PD, polymorphisms of the COMT, MAO, DAT, NET, and 5- HTT genes may change the levels of biogenic amines and their metabolic products. The currently available therapies for PD improve the symptoms but do not halt the progression of the disease. The most effective treatment for PD patients is therapy with L-dopa. Combined therapy for PD involves a DA agonist and decarboxylase, MAOs and COMT inhibitors, and is the current optimal form of PD treatment maintaining monoamine balance.
Keywords: COMT, MAO, Monoamine transporters polymorphism, PD.
Current Genomics
Title:Polymorphism of the COMT, MAO, DAT, NET and 5-HTT Genes, and Biogenic Amines in Parkinson’s Disease
Volume: 14 Issue: 8
Author(s): Jolanta Dorszewska, Michal Prendecki, Anna Oczkowska, Agata Rozycka, Margarita Lianeri and Wojciech Kozubski
Affiliation:
Keywords: COMT, MAO, Monoamine transporters polymorphism, PD.
Abstract: Epinephrine (E) and sympathetic nerve stimulation were described by Thomas Renton Elliott in 1905 for the first time. Dopamine (DA), norepinephrine (NE), E, and serotonin (5-HT) belong to the classic biogenic amines (or monoamines). Parkinson’s disease (PD) is among the diseases in which it has been established that catecholamines may account for the neurodegeneration of central and peripheral catecholamine neural systems. PD is a chronic and progressive neurological disorder characterized by resting tremor, rigidity, and bradykinesia, affecting 2% of individuals above the age of 65 years. This disorder is a result of degeneration of DA-producing neurons of the substantia nigra and a significant loss of noradrenergic neurons in the locus coeruleus. In PD and other related neurodegerative diseases, catecholamines play the role of endogenous neurotoxins. Catechol-O-methyltransferase (COMT) and/or monoamine oxidase (MAO) catalyze the metabolism of monoamines. However, the monoamine transporters for DA, NE, and 5-HT namely DAT, NET, and SERT, respectively regulate the monoamine concentration. The metabolism of catecholamines and 5-HT involves common factors. Monoamine transporters represent targets for many pharmacological agents that affect brain function, including psychostimulators and antidepressants. In PD, polymorphisms of the COMT, MAO, DAT, NET, and 5- HTT genes may change the levels of biogenic amines and their metabolic products. The currently available therapies for PD improve the symptoms but do not halt the progression of the disease. The most effective treatment for PD patients is therapy with L-dopa. Combined therapy for PD involves a DA agonist and decarboxylase, MAOs and COMT inhibitors, and is the current optimal form of PD treatment maintaining monoamine balance.
Export Options
About this article
Cite this article as:
Dorszewska Jolanta, Prendecki Michal, Oczkowska Anna, Rozycka Agata, Lianeri Margarita and Kozubski Wojciech, Polymorphism of the COMT, MAO, DAT, NET and 5-HTT Genes, and Biogenic Amines in Parkinson’s Disease, Current Genomics 2013; 14 (8) . https://dx.doi.org/10.2174/1389202914666131210210241
DOI https://dx.doi.org/10.2174/1389202914666131210210241 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development and Validation of a Stability-Indicating HPLC Method for the Assay of Carvedilol in Pure and Tablet Dosage Forms
Current Pharmaceutical Analysis Development and Characterization of a New PVC-Membrane Electrode for Selective Sensing of K+ Ion
Current Analytical Chemistry Effects of Therapeutic Hypothermia on the Glial Proteome and Phenotype
Current Protein & Peptide Science An Insight into the Therapeutic Potential of Major Coffee Components
Current Drug Metabolism Lifestyle Interventions in Pregnancy: Myths and Facts, A Commentary
Current Women`s Health Reviews Advanced Glycation End Products and Cardiovascular Disease
Current Diabetes Reviews Autophagy Inhibition Preserves Tight Junction of Human Cerebral Microvascular Endothelium Under Oxygen Glucose Deprivation
Current Neurovascular Research Editorial (Thematic Issue: All Roads of Renal Hypertension Lead to or Come from CKD)
Current Hypertension Reviews Sam Domains in Multiple Diseases
Current Medicinal Chemistry Evaluation of Salivary Melatonin Levels in HIV-positive Patients: A Historical Cohort Study
Reviews on Recent Clinical Trials The Promises and Challenges of the Use of Genomics in the Prescription of Exercise in Hypertension
Current Hypertension Reviews Editorial (Current and Emerging Pharmacological Therapies of Ischaemic Stroke)
CNS & Neurological Disorders - Drug Targets Role of the Sex Hormone Estrogen in the Prevention of Lipid Disorder
Current Medicinal Chemistry Subject Index To Volume 1
Recent Patents on Anti-Cancer Drug Discovery Design and Study of Piracetam-like Nootropics, Controversial Members of the Problematic Class of Cognition-Enhancing Drugs
Current Pharmaceutical Design Validating Immunotherapy in Alzheimer’s Disease: The EB101 Vaccine
Current Pharmaceutical Design The Expanding Universe of Neurotrophic Factors: Therapeutic Potential in Aging and Age-Associated Disorders
Current Pharmaceutical Design Necroptosis Signaling Pathways in Stroke: From Mechanisms to Therapies
Current Neuropharmacology Origins, Controversies and Recent Developments of the MCI Construct
Current Alzheimer Research Aquaporin Water Channels in Central Nervous System
Current Neurovascular Research